Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.

Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C.

Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699. eCollection 2019. Review.

2.

Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.

Bereshchenko O, Lo Re O, Nikulenkov F, Flamini S, Kotaskova J, Mazza T, Le Pannérer MM, Buschbeck M, Giallongo C, Palumbo G, Li Volti G, Pazienza V, Cervinek L, Riccardi C, Krejci L, Pospisilova S, Stewart AF, Vinciguerra M.

Clin Epigenetics. 2019 Aug 22;11(1):121. doi: 10.1186/s13148-019-0724-z.

3.

Phenotype evolution and health issues of adults with Beckwith-Wiedemann syndrome.

Gazzin A, Carli D, Sirchia F, Molinatto C, Cardaropoli S, Palumbo G, Zampino G, Ferrero GB, Mussa A.

Am J Med Genet A. 2019 Sep;179(9):1691-1702. doi: 10.1002/ajmg.a.61301. Epub 2019 Jul 24.

PMID:
31339634
4.

The Role of New Technologies in Myeloproliferative Neoplasms.

Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, Cattaneo D, Iurlo A.

Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019. Review.

5.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619. [Epub ahead of print]

PMID:
30985017
6.

Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study.

Pappalardo A, Currenti W, Ponzio R, Mellini G, Nicolosi D, Longhitano L, Tibullo D, Castorina S, Palumbo G.

Blood Transfus. 2019 May;17(3):196-199. doi: 10.2450/2019.0181-18. Epub 2019 Feb 18.

7.

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.

Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.

Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

8.

CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia.

Rossi F, Tortora C, Palumbo G, Punzo F, Argenziano M, Casale M, Di Paola A, Locatelli F, Perrotta S.

Int J Mol Sci. 2019 Feb 28;20(5). pii: E1049. doi: 10.3390/ijms20051049.

9.

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.

Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.

Br J Haematol. 2019 May;185(3):468-479. doi: 10.1111/bjh.15801. Epub 2019 Feb 15.

PMID:
30768678
10.

α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.

Camiolo G, Tibullo D, Giallongo C, Romano A, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA.

Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609.

11.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
12.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
13.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28. Review.

PMID:
30448050
14.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5. No abstract available.

PMID:
30321784
15.

Biostimulant Potential of Humic Acids Extracted From an Amendment Obtained via Combination of Olive Mill Wastewaters (OMW) and a Pre-treated Organic Material Derived From Municipal Solid Waste (MSW).

Palumbo G, Schiavon M, Nardi S, Ertani A, Celano G, Colombo CM.

Front Plant Sci. 2018 Jul 20;9:1028. doi: 10.3389/fpls.2018.01028. eCollection 2018.

16.

Next-Generation Sequencing Reveals A JAGN1 Mutation in a Syndromic Child With Intermittent Neutropenia.

Cifaldi C, Serafinelli J, Petricone D, Brigida I, Di Cesare S, Di Matteo G, Chiriaco M, De Vito R, Palumbo G, Rossi P, Palma P, Cancrini C, Aiuti A, Finocchi A.

J Pediatr Hematol Oncol. 2019 May;41(4):e266-e269. doi: 10.1097/MPH.0000000000001256.

PMID:
30044346
17.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
18.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.

Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D.

Br J Haematol. 2018 Sep;182(5):701-704. doi: 10.1111/bjh.15450. Epub 2018 Jul 9.

PMID:
29984826
19.

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.

Expert Rev Mol Diagn. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3.

PMID:
29707981
20.

Iron toxicity - Its effect on the bone marrow.

Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.

Blood Rev. 2018 Nov;32(6):473-479. doi: 10.1016/j.blre.2018.04.004. Epub 2018 Apr 13. Review.

PMID:
29699840

Supplemental Content

Loading ...
Support Center